Stada and Xbrane Biopharma have chalked up another approval for their Ximluci (ranibizumab) biosimilar, after the UK’s Medicines and Healthcare products Regulatory Agency issued a marketing authorization for the Lucentis rival in Great Britain.
The British marketing authorization was granted via the EC Decision Reliance Procedure, with the MHRA relying on the European Commission’s...